NASDAQ:PBLA
Panbela Therapeutics Inc. Stock News
$0.420
+0.0400 (+10.53%)
At Close: Jun 21, 2024
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
01:36am, Monday, 20'th May 2024
Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
07:30pm, Wednesday, 15'th May 2024
Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants James Carbonara - IR, HaydenIR Jennifer Simpson - President & CEO Susan Horvath - CF
Panbela Provides Business Update and Reports Q1 2024 Financial Results
04:10pm, Wednesday, 15'th May 2024
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet m
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
04:15pm, Wednesday, 01'st May 2024
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
08:00am, Tuesday, 30'th Apr 2024
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
08:00am, Monday, 22'nd Apr 2024
Trial's lower-than-expected event rate suggests improved survival outcomes Trial's lower-than-expected event rate suggests improved survival outcomes
Panbela Announces Poster Presentation at American Association for Cancer Research:
08:00am, Thursday, 18'th Apr 2024
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models Ivospemin/doxorubicin combination modulates polyamine metabolism to improve surviva
Panbela Announces Transfer to OTCQB Market
05:29pm, Tuesday, 16'th Apr 2024
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients wi
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
09:49pm, Tuesday, 26'th Mar 2024
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
04:10pm, Tuesday, 26'th Mar 2024
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
04:15pm, Tuesday, 12'th Mar 2024
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients w
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
07:50am, Friday, 23'rd Feb 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
08:00am, Thursday, 15'th Feb 2024
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients wit
Panbela Announces Closing of Approximately $9.0 Million Public Offering
07:00am, Thursday, 01'st Feb 2024
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet